Vanflyta (quizartinib) — Highmark

Initial criteria

• age ≥ 18 years
• diagnosis of newly diagnosed AML
• EITHER:
• - receiving induction therapy using Vanflyta in combination with standard cytarabine and anthracycline induction therapy
• - OR receiving consolidation therapy using Vanflyta in combination with standard cytarabine consolidation therapy
• - OR receiving maintenance therapy using Vanflyta as monotherapy
• FLT3-ITD-positive as detected by an FDA-approved test

Reauthorization criteria

• Prescriber attests member is tolerating therapy AND has experienced a therapeutic response defined as disease improvement OR delayed disease progression

Approval duration

12 months